BCAS2 Rabbit Polyclonal Antibody

CAT#: TA306932

Rabbit Polyclonal BCAS2 Antibody

Product Images

Western blot analysis of BCAS2 in MCF7 cell lysate with BCAS2 antibody at (A) 0.5 and (B) 1 ug/mL.

• 

  Immunohistochemistry of BCAS2 in human breast carcinoma with BCAS2 antibody at 5 ug/mL.

• 

  Immunofluorescence of BCAS2 in human breast carcinoma tissue with BCAS2 antibody at 20 ug/mL.

Specifications

Product Data

• Applications: IF, IHC, WB
• Recommended Dilution: WB: 0.5 - 1 ug/mL, ICC: 5 ug/mL, IF: 20 ug/mL
• Reactivities: Human, Mouse, Rat
• Host: Rabbit
• Isotype: IgG
• Clonality: Polyclonal
• Immunogen: BCAS2 antibody was raised against a 14 amino acid peptide near the carboxy terminus of human BCAS2.
• Formulation: PBS containing 0.02% sodium azide.
• Concentration: 1ug/ul
• Purification: Affinity chromatography purified via peptide column
• Conjugation: Unconjugated
• Storage: Store at -20°C as received.
• Stability: Stable for 12 months from date of receipt.
• Gene Name: breast carcinoma amplified sequence 2
• Database Link:
  NP_005863
  Entrez Gene 68183 MouseEntrez Gene 295334 RatEntrez Gene 10286 Human
  UniProt ID O75934
• Background: BCAS2 was identified through differential display analysis as an mRNA species that was overexpressed in MCF7 and BT-20 breast cancer cell lines. The chromosomal region containing this gene, 1p13.3021, is amplified in these cells lines. BCAS2 is a transcriptional cofactor that enhances estrogen receptor-mediated gene expression, and directly interacts with the tumor suppressor p53 to reduce p53 transcriptional activity by reducing p53 protein level in the absence of DNA damage. Deprivation of BCAS2 through RNA inhibition induces apoptosis in p53-wild type cells, but causes G2-M arrest in p53-null or –mutant cells; this effect was reversed with the expression of ectopic BCAS2. BCAS2 may thus be potentially useful as a therapeutic target in the treatment of cancer.
• Synonyms: DAM1; Snt309; SPF27

Reference Data

• Protein Pathways: Spliceosome